Top Markets
#1 GEKKO GEKKO +52.86%
#2 Helium Helium +48.09%
#3 Pons Pons +29.16%
#4 龙虾 (Lobster) 龙虾 (Lobster) +18.73%
#5 ADO Protocol ADO Protocol +18.06%
#6 Main Street Yield Main Street Yield +17.48%
#7 Collect on Fanable Collect on Fanable +16.65%
#8 OpenGradient OpenGradient +12.52%
#9 o1.exchange o1.exchange +12.13%
#10 Nillion Nillion +10.62%
Coin of the day
GEKKO GEKKO
Settings
Language
ENGLISH
Currency
USD
Theme
China Resources Boya Bio-pharmaceutical Group Co., Ltd. China Resources Boya Bio-pharmaceutical Group Co., Ltd.

China Resources Boya Bio-pharmaceutical Group Co., Ltd.

300294
Rank in Stocks #9112
Established in 1993 and headquartered in Fuzhou, China, China Resources Boya... Established in 1993 and headquartered in Fuzhou, China, China Resources Boya Bio-pharmaceutical Group Co., Ltd. (formerly Boya Bio-pharmaceutical Group Co., Ltd.) is a comprehensive pharmaceutical enterprise operating across China. The company is engaged in the research, development, production, and sale of a diverse portfolio, primarily focusing on blood products, diabetes medications, and various biochemical and chemical pharmaceuticals. Its extensive range of blood-derived products includes human fibrinogen, human albumin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, and freeze-dried intravenous human immunoglobulin. For diabetes management, the company offers metformin hydrochloride (both tablets and enteric-coated versions), pioglitazone hydrochloride dispersible tablets, glimepiride tablets, and calcium dobesilate capsules. Additionally, it produces specialized injections such as compound osteotide, oxytocin, and heparin sodium, which are utilized across numerous medical fields, including general medicine, hepatitis treatment, gynecology, and immunomodulatory applications.
Share Price
$2.16
Last synced: 2026-08-28
Market Cap
$1.09B
Change (1 day)
-0.07%
Change (1 year)
-42.06%
Country
CN
Trade China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294)

Category

Healthcare
P/E ratio for China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294)
P/E ratio as of 2026 TTM: 0
According to China Resources Boya Bio-pharmaceutical Group Co., Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for China Resources Boya Bio-pharmaceutical Group Co., Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.